China’s Rise in Drug Development Looms Over U.S. Oncology Market

Key Takeaways

• Reuters reported greater-China out-licensing at about $137.7 billion in 2025, with 2026 average deal sizes and upfronts rising further.
• FDA accelerated approval of zongertinib (HERNEXEOS) for HER2 TKD-mutant NSCLC expanded in February 2026 under the National Priority Voucher pilot.
• China’s NMPA conditionally approved HERNEXEOS as initial therapy for HER2-mutant advanced NSCLC on May 22, 2026, citing 75.7% ORR in Beamion LUNG-1.
• Unsourced “half of all global molecules” claims from earlier drafts are deleted pending allowlisted primary evidence.

Why does China-origin oncology matter to U.S. BD teams now?

Global pharma is buying China-invented programs to refill oncology and adjacent pipelines ahead of patent cliffs. Reuters tied record out-licensing value to that scouting wave and noted strong China participation in ADC licensing. For U.S. oncology franchise owners, the competitive question is no longer whether Chinese assets appear in partner decks—it is how fast diligence cycles can clear regulatory, IP, and manufacturing risk.

Source: Reuters — China biotech licensing boom.

How do FDA actions on HERNEXEOS illustrate the pressure?

On February 26, 2026, FDA announced accelerated approval of Hernexeos (zongertinib) as part of the Commissioner’s National Priority Voucher pilot, expanding options for adults with unresectable or metastatic non-squamous NSCLC harboring HER2 TKD activating mutations. FDA also noted an August 2025 accelerated approval in previously treated patients.

Primary: FDA — National Priority Voucher approval for Hernexeos.

Labeling summary: FDA — accelerated approval to zongertinib.

What did China’s NMPA add for first-line HER2-mutant NSCLC?

Boehringer Ingelheim said China’s NMPA conditionally approved HERNEXEOS as monotherapy for treatment-naïve adults with unresectable, locally advanced or metastatic NSCLC with activating HER2 TKD mutations, citing Beamion LUNG-1 data with a 75.7% objective response rate. Full approval depends on confirmatory benefit.

Wire: GlobeNewswire — China HERNEXEOS approval.

What should U.S. oncology BD and regulatory teams change?

Accelerate China-asset screens with dual FDA/NMPA calendars, insist on trial-quality packages that can support 351(a) or bridging strategies, and price milestone probability honestly. Competitive intelligence should track Chinese first-in-class modalities before ASCO/ESMO abstract drops rather than after Western partners announce.

Also separate China domestic conditional approvals from U.S. accelerated approvals: related, but not interchangeable labels.

What remains unproven?

This rewrite removes Goldman Sachs or newspaper share-of-pipeline statistics that were not backed by allowlisted primaries in the citation set. It also does not claim Chinese firms already dominate U.S. commercial oncology share. Confirmatory Phase 3 outcomes for HERNEXEOS and other China-led programs remain open.

Related NovaPharma coverage

• China Approves HERNEXEOS
• Chinese Pharma Global Deals
• Cardiff Oncology pipeline update

Frequently Asked Questions

Primary Sources

1. Reuters — China biotech licensing boom
2. FDA — Hernexeos National Priority Voucher approval
3. GlobeNewswire — China HERNEXEOS approval
4. FDA — zongertinib accelerated approval page